2025 marks a breakthrough year for in vivo gene therapies

Dec. 30, 2025

Gene editing technologies are moving forward in preclinical development with innovative strategies designed to treat diseases at their root and even reverse them.

Medical technology Drug design, drug delivery and technologies Endocrine/metabolic Genetic/congenital Neonatal/pediatrics Neurology/psychiatric Rare disease Gene therapy

Today's news in brief

BioWorld

BioWorld briefs for May 29, 2026.

TROP2 ADCs progress into first-line for lung, breast cancers

BioWorld

Multiple updates on TROP2-directed antibody-drug conjugates (ADCs) for lung and breast cancers highlight both progress made and opportunities for improvement for...

Illustration of antibodies and viral infection

New evidence links autoimmunity to long COVID symptoms

BioWorld

Recent findings are reshaping current understanding of the post-infection landscape of SARS-CoV-2. Although previous studies had already suggested that...

Will Ovid’s golden age of KCC2 metamorph CNS?

BioWorld

The “deep dive” April 8 by Ovid Therapeutics Inc. into potassium-chloride co-transporter 2 (KCC2) research included company officials and independent experts in...

Liver with hepatitis viruses, blood cells

Breakthrough as GSK’s bepirovirsen clears 19% of chronic hep B infections

BioWorld

GSK plc has announced a breakthrough in the treatment of chronic hepatitis B, reporting a functional cure rate of 19% across two phase III trials of its antisense...